Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.